Molecular pathways: translational potential of deubiquitinases as drug targets
1Department of Oncology-Pathology, Karolinska Institute, Stockholm and Padraig.Darcy@ki.se.
Abstract:
The ubiquitin proteasome system (UPS) is the main system for controlled protein degradation and a key regulator of fundamental cellular processes. The dependency of cancer cells on a functioning UPS coupled with the clinical success of bortezomib for the treatment of multiple myeloma have made the UPS an obvious target for drug development. Deubiquitinases (DUB) are components of the UPS that encompass a diverse family of ubiquitin isopeptidases that catalyze the removal of ubiquitin moieties from target proteins or from polyubiquitin chains, resulting in altered signaling or changes in protein stability. Increasing evidence has implicated deregulation of DUB activity in the initiation and progression of cancer. The altered pattern of DUB expression observed in many tumors can potentially serve as a clinical marker for predicting disease outcome and therapy response. The finding of DUB overexpression in tumor cells suggests that they may serve as novel targets for the development of anticancer therapies. Several specific and broad-spectrum DUB inhibitors are shown to have antitumor activity in preclinical in vivo models with low levels of systemic toxicity. Future studies will hopefully establish the clinical potential for DUB inhibitors as a strategy to treat cancer.
Insights
The ubiquitin proteasome system (UPS) is crucial for cell function and cancer growth. Inhibiting deubiquitinases (DUBs), key UPS components, shows promise as a novel cancer therapy with low toxicity in early studies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The ubiquitin proteasome system (UPS) regulates essential cellular processes through controlled protein degradation.
- Cancer cells often depend on a functional UPS, making it a validated therapeutic target, as demonstrated by bortezomib's success in multiple myeloma.
- Deubiquitinases (DUBs) are critical UPS enzymes that remove ubiquitin, influencing protein stability and signaling pathways.
Purpose of the Study:
- To explore the role of DUBs in cancer initiation and progression.
- To evaluate DUBs as potential biomarkers for cancer prognosis and treatment response.
- To investigate the therapeutic potential of DUB inhibitors in preclinical cancer models.
Main Methods:
- Review of existing literature on UPS, DUBs, and their role in cancer.
- Analysis of DUB expression patterns in tumor cells.
- Evaluation of preclinical in vivo data for DUB inhibitors' antitumor activity and toxicity.
Main Results:
- Deregulation of DUB activity is increasingly implicated in cancer development.
- Altered DUB expression patterns in tumors may serve as predictive clinical markers.
- Preclinical studies demonstrate that DUB inhibitors possess antitumor activity with manageable systemic toxicity.
Conclusions:
- DUBs represent promising novel targets for anticancer drug development.
- DUB inhibitors have shown significant potential in preclinical models.
- Further research is warranted to establish the clinical utility of DUB inhibitors for cancer treatment.
More Related Videos
Related Concept Videos
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: